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Background: Glycosylated hemoglobin A1C (HbA1c) has been widely recognized as a marker for predicting the
severity of diabetes mellitus (DM) and several cardiovascular diseases. However, whether HbA1c could predict the
severity and clinical outcomes in patients with stable coronary artery disease (CAD) remains largely unknown. We
determine relationship of HbA1c with severity and outcome in patients with stable CAD.
Methods: We enrolled 1433 patients with stable angina who underwent coronary angiography and were followed
up for an average 12 months. The patients were classified into three groups by tertiles of baseline HbA1c level (low
group <5.7%, n = 483; intermediate group 5.7 - 6.3%, n = 512; high group >6.3%, n = 438). The relationships between
the plasma HbA1c and severity of CAD and early clinical outcomes were evaluated.
Results: High HbA1c was associated with three-vessel disease. Area under the receivers operating characteristic
curve (AUC = 0.67, 95% CI: 0.63-0.71, P < 0.001) and multivariate logistic regression analysis suggested that HbA1C
was an independent predictor of severity of CAD (OR = 1.60, 95% CI: 1.29-1.99, P < 0.001) even after adjusting for
gender, age, risk factor of CAD, lipid profile and fasting blood glucose. During follow-up, 133 patients underwent
pre-specified outcomes. After adjusting for multiple variables in the Cox regression model, HbA1C remained to be
an independent predictor of poor prognosis (HR = 1.28, 95% CI: 1.12-1.45, P < 0.001).
Conclusions: We concluded that high level of baseline HbA1c appeared to be an independent predictor for the
severity of CAD and poor outcome in patients with stable CAD.
Keywords: Hemoglobin A1c, Stable angina pectoris, Coronary artery disease, OutcomeIntroduction
Glycosylated Hemoglobin A1c (HbA1c) is a pivotal bio-
marker reflecting both fasting and postprandial plasma
glucose concentration over the preceding 2–3 months
[1,2]. And also, it has been regarded as an important tool
in diabetes diagnosis and management [1-5]. It has been
reported that elevated HbA1c levels probably mean long-
term insulin resistance and severe consequences such as
hyperglycemia, dyslipidemia, hypercoagulability, and sys-
tem inflammatory response [5-7]. Furthermore, several* Correspondence: lijianjun938@yahoo.com
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unless otherwise stated.studies have demonstrated a positive relationship between
elevated HbA1c and poor outcome in the setting of
general population, acute coronary syndrome (ACS), acute
myocardial infarction (AMI), heart failure, pancreatitis,
and even patients after coronary artery bypass surgery and
drug-eluting stent (DES) implantation with and without
primary diabetes mellitus (DM) [8-17]. Although con-
sistent evidences have supported that optimal control of
HbA1c at a target value can confer to a lower incidence
of microvascular complications both in type 1 and type
2 DM, the association of high levels of HbA1c with macro-
vascular disease such as stable coronary disease remains
controversial [11,12,18-21].
Moreover, a few population studies suggested that
the values of plasma HbA1c should be perceived as atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cause it might exhibit a significantly detrimental role even
when it was in “normal” or relatively low levels [6,7]. More
interestingly, it has also been showed that a higher level of
circulating HbA1c was related to elevated inflammatory
markers such as C-reactive protein (CRP), fibrinogen and
white blood cell count, which were routinely available and
well established predictors of future mortality. Therefore,
it might provide meaningfully predictive value than either
alone [6,7]. Meanwhile, several previous studies have dem-
onstrated a positive correlation of high HbA1c levels with
severity of coronary artery disease while the clinical sig-
nificance of previous observation were apparently limited
by either a retrospective design manner or small sample
size [22-26]. According to the best of our knowledge, data
from larger sample in a prospective design regarding the
value of plasma HbA1c in predicting the disease severity
in patients with stable coronary artery disease (CAD) is
not currently available. Furthermore, whether the elevated
HbA1c levels could also provide any additional prognostic
information for those patients with stable CAD remains
to be determined.
The aim of this study, therefore, was to prospectively in-
vestigate the predictive power of HbA1c levels for the se-
verity and the early outcome in patients with stable CAD.
Materials and methods
Study population
This was a single center, prospective follow-up study.
From June 2011 through March 2012, we prospectively
enrolled 1433 consecutive women and men (70.3%) aged
19 to 86 years (average age 58.29 years) with typical stable
exertional angina pectoris referred for selective coronary
angiography at our center. Patients with ACS, signifi-
cant hematologic disorders (white cell count <3.5×109/L
or >20×109/L), infectious or inflammatory disease, se-
vere liver and/or renal insufficiency were excluded from
the present study. Data including the demographic, clin-
ical, laboratory findings and angiographic examination
were collected from all patients.
The protocol of this study was approved by Fu Wai
hospital ethics committee, and complied with the Dec-
laration of Helsinki. The informed consent was obtained
from all participants.
Diagnostic criteria
Hypertension was defined by SBP ≥ 140 mmHg and/or
DBP ≥ 90 mmHg, or currently receiving antihypertensive
medication [27]. The diagnostic criteria recommended
by WHO for diabetes mellitus were used [28]. According
to these criteria, we diagnosed patients as having dia-
betes with fasting blood glucose values ≥126 mg/dl, or
2-h blood glucose ≥200 mg/dl, or under the active
treatment with insulin or oral hypoglycemic agents.Hyperlipidemia was considered to be present in patients
with fasting total cholesterol (TC) ≥200 mg/dl or trigly-
ceride (TG) ≥150 mg/dl. CAD was defined as the pres-
ence of significant obstructive stenosis at least 50% of
the vessel lumen diameters in any of the main coronary
arteries by at least two independent senior interventional
cardiologists based on quantity coronary angiography.
The severity of CAD was scored as 0 (absent or minimal
atherosclerotic involvement), 1 (single vessel disease),
2 (two-vessel disease), 3 (three-vessel disease and/or left
main stem disease and/or equally affected of left anterior
descending and left circumflex branch). The left ventricu-
lar ejection fraction was evaluated by echocardiograph
using the area-length methods or modified Simpson’s rule.
Biochemical examination
Venous blood samples were obtained from each patient
at baseline on admission. HbA1c levels were measured
using the Tosoh G7 Automate HPLC Analyzer (TOSOH
Bioscience, Japan). The concentrations of high-sensitivity
C-reactive protein (hs-CRP) were determined using immu-
noturbidimetry (Beckmann Assay 360, Bera, Calif., USA).
TC and TG were measured by enzymatic methods and
high-density lipoprotein cholesterol by a direct method
(Roche Diagnostics, Basel, Switzerland). Low-density
lipoprotein cholesterol was obtained by Friedewald’s for-
mula (if fasting triglycerides <3.39 mmol/l) or by ultra-
centrifugation. Apolipoprotein B was measured by an
immune-turbidimetric method (Tina-quant, Roche Diag-
nostics) calibrated against the World Health Organization/
International Federation of Clinical Chemistry reference
standard SP3–07. All other included biomarkers were ana-
lyzed by standard hematological and biochemical tests.
Follow up
All patients were subjected to follow up throughout the
study period with an average of 12 months by a tele-
phone and/or clinical interview. The pre-specified clin-
ical end points were defined as cardiac death, nonfatal
MI, revascularization, and re-hospitalization due to at-
tack of acute coronary syndrome (ACS).
Statistical analysis
Continuous variables and categorical variables were ana-
lyzed by the chi-squared statistic tests, the one-way ana-
lysis of variance test, or the Kruskal-Wallis test when
appropriate. Receivers operating characteristic (ROC)
curves were constructed at the most discriminating cutoff
point values to predict CAD. The relationship of HbA1c
with angiographic findings were evaluated by univariate
and multivariate logistic regression models (including po-
tential factors such as age, gender, cardiac risk factors,
medicine treatment, DES implantation, baseline lipid pro-
file and other hematological index) using forward stepwise
Table 1 Baseline characteristics according to the tertiles of serum hemoglobin A1C levels
Variables Tertiles of serum hemoglobin A1C levels (%) P-value
Total (n = 1433) Low (<5.7; n = 483) Intermediate
(5.7 ~ 6.3; n = 512)
High (>6.3; n = 438)
Demographic
Age, years 58.3 ± 10.2 55.5 ± 10.8 59.6 ± 9.6 59.8 ± 9.5 <0.001
Male gender 1008(69.9) 365(75.6) 350(68.3) 293(66.9) 0.008
Risk factors Body mass index (kg/m2) 25.5 ± 3.2 25.0 ± 3.0 25.4 ± 3.3 26.0 ± 3.2 <0.001
Current Smoking 770(53.4) 271(56.1) 272(53.1) 227(51.8) 0.404
Hypertension 909(63.4) 280(58.0) 317(61.9) 312(71.2) <0.001
Diabetes mellitus 374(26.1) 89(18.4) 93(18.2) 192(43.8) <0.001
Hyperlipidemia 1064(74.2) 306(63.4) 393(76.8) 365(83.3) <0.001
Peripheral vascular disease 26(1.8) 6(1.2) 11(2.1) 9(2.1) 0.509
Prior Stroke 68(4.7) 16(3.3) 27(5.3) 25(5.7) 0.182
Family history of CAD 158(11.0) 44(9.1) 55(10.7) 59(13.5) 0.104
Laboratory date
LVEF (%) 62.2 ± 8.1 62.5 ± 8.2 62.1 ± 8.2 62.2 ± 7.9 0.672
NT-pro-BNP (fmol/mL) 710.4 ± 515.7 663.9 ± 422.7 720.8 ± 492.3 749.5 ± 622.1 0.036
FBG (mmol/L) 5.5 ± 1.5 6.8 ± 2.1 5.0 ± 0.6 4.7 ± 0.6 <0.001
Haemoglobin (g/L) 139.9 ± 15.1 141.5 ± 14.9 139.7 ± 14.7 138.3 ± 15.9 0.006
Leucocyte count (109/L) 6.4 ± 1.6 6.2 ± 1.6 6.4 ± 1.6 6.6 ± 1.7 0.002
Platelet count (109/L) 205.1 ± 60.7 201.8 ± 68.6 208.4 ± 58.6 204.9 ± 53.7 0.221
Fibrinogen (g/L) 3.2 ± 0.8 2.9 ± 0.6 3.2 ± 0.7 3.3 ± 0.9 <0.001
D-dimer (mg/dL) 0.4 ± 0.7 0.3 ± 0.4 0.4 ± 0.6 0.3 ± 1.0 0.023
hs-CRP (mg/L) 2.9 ± 3.6 2.1 ± 2.9 3.0 ± 3.5 3.6 ± 4.1 <0.001
Endothelin-1 (fmol/mL) 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 0.492
Albumin (g/L) 41.8 ± 3.5 41.6 ± 3.3 41.9 ± 3.8 41.8 ± 3.4 0.491
Cr (umol/L) 75.6 ± 16.2 75.4 ± 13.8 75.4 ± 17.1 76.2 ± 17.5 0.686
UA (mmol/L) 347.4 ± 4.2 354.0 ± 83.3 348.8 ± 80.5 338.5 ± 88.8 0.017
Lipid profile
Triglycerides (mmol/L) 4.2 ± 1.1 4.1 ± 0.9 4.2 ± 1.1 4.1 ± 1.1 0.008
Total cholesterol (mmol/L) 4.2 ± 1.1 4.0 ± 0.9 4.2 ± 1.1 4.2 ± 1.1 0.077
LDL-C (mmol/L) 2.5 ± 0.9 2.5 ± 0.9 2.5 ± 0.8 2.5 ± 0.9 0.497
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.2 1.1 ± 0.3 0.051
Lipoprotein (a) (mg/L) 236.9 ± 244.6 220.6 ± 224.7 265.6 ± 263.4 221.4 ± 240.4 0.004
ApoA (g/L) 1.5 ± 0.3 1.5 ± 0.3 1.5 ± 0.2 1.5 ± 0.3 0.920
ApoB (g/L) 1.1 ± 0.3 1.0 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.157
Medical treatment
Aspirin 1358(94.8) 444(91.9) 490(95.7) 424(96.8) 0.002
Clopidogrel 1297(90.5) 416(86.1) 473(92.4) 408(93.2) <0.001
Beta-blocker 1129(78.8) 351(72.7) 415(81.1) 363(82.9) <0.001
ACE-I 424(29.6) 132(27.3) 162(31.6) 130(29.7) 0.389
Statin 1332(93.0) 429(88.8) 486(94.9) 417(95.2) <0.001
DES implantation 250(17.4) 60(12.4) 109(21.3) 81(18.5) 0.001
CAD = Coronary artery disease; LV-FE = Left ventricular ejection fraction; hs-CRP = high sensitivity C-reactive protein; LDL-C = Low density lipoprotein cholesterol;
HDL-C = High density lipoprotein cholesterol; ACE-I = Angiotensin converting enzyme inhibitors; DES = Drug eluting stent.
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month outcomes was determined with Cox proportional
hazard models using forward stepwise selection process.
Event-free survival curves were constructed using the
Kaplan-Meier methods and compared using log-rank test.
All analyses were performed using SPSS version19.0 soft-
ware (Chicago, Illinois, USA).Results
Baseline characteristics
The baseline demographic, clinical characteristics and
laboratory findings according to tertiles of HbA1c (low
group <5.7%, n = 483; intermediate group 5.7-6.3%, n =
512; high group >6.3%, n = 438) were shown in Table 1.
The distribution of HbA1c was shown in Figure 1. As
shown in Table 1, patients with the higher HbA1c levels
were more likely to be older, female, and have elevated
body mass index (BMI) and a prior history of hyperten-
sion and dyslipidemia. Meanwhile, the pattern of the
inflammation-related biomarkers such as hs-CRP, leuco-
cyte count, fibrinogen and D-dimer were significantly
unbalanced among the patients. Additionally, patients
with the higher levels of HbA1c received the more drug
administrations and DES implantations.Figure 1 Distribution of baseline serum hemoglobin A1C level in theHbA1c for predicting the extent of CAD
There were a statistically significant correlation between
the tertiles of plasma HbA1C and angiographic charac-
teristics (chi-squared for trend, P <0.001, Figure 2). The
multivariate logistic regression analysis showed that the
plasma HbA1C level was an independent predictor of
the presence of CAD after adjusting for conventional risk
factors of CAD (OR = 1.60, 95% CI: 1.29-1.99, P <0.001,
Table 2) . Area under the ROC curves (AUC) analysis also
indicated the well discriminatory power of HbA1c levels
for the presence of CAD (AUC= 0.67, 95% CI: 0.63-0.71,
P <0.001, Figure 3).HbA1c for predicting the early outcomes
The population of the present study was followed up for
an average of 12 months follow-up (ranged from 14 to
577 days). During follow-up, 133 patients suffered from
adverse outcome (Figure 4). There were a significant
association between baseline plasma HbA1c levels and
incidence of total outcome, revascularization (P = 0.001
and P = 0.016, respectively), but not for nonfatal MI or
cardiac death (P = 0.100 and 0.559, respectively) during
follow-up. The multivariate analysis showed that plasma
HbA1C remained to be an independent predictors ofstudy population.
Figure 2 Association of tertiles of serum hemoglobin A1C levels and extent of coronary artery disease.
Hong et al. Lipids in Health and Disease 2014, 13:89 Page 5 of 9
http://www.lipidworld.com/content/13/1/89overall outcome for patients with stable angina (HR = 1.28,
95% CI: 1.12-1.45, P <0.001) except for the family history
of CAD and numbers of affected coronary arteries (Table 3)
after adjusting for all potential confounders including
age, gender, cardiovascular risk factors, medicine treat-
ment, DES implantation, baseline lipid profile and other
hematological index.
Kaplan-Meier curves for cumulative event-free survival
based on the tertiles of baseline HbA1c were presented
in Figure 5. As presented in Figure 5, elevated plasma
HbA1c (>6.3%) were generally associated with increased
early adverse outcome (P < 0.001). However, subgroup
analysis indicated the predictive power of plasma HbA1c
was only found in patients with stable angina who had a
history of DM (P < 0.001), but not in populations with-
out a history of DM (P = 0.324).Table 2 Unadjusted and adjusted predictive value of
serum hemoglobin A1C levels for coronary artery disease
Variables Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
Gender 3.06(2.00-4.68) <0.001 3.34(2.41-4.64) <0.001
Age 1.04(1.03-1.06) <0.001 1.04(1.02-1.06) <0.001
Dyslipidemia 2.26(1.62-3.17) <0.001 2.33(1.69-3.22) <0.001
Hemoglobin A1c 1.76(1.32-2.34) <0.001 1.60(1.29-1.99) <0.001Discussion
The present study prospectively investigated the predict-
ive value of plasma HbA1c for the severity of CAD and
mortality in patients with stable CAD. Consistent with
previous small sample size studies [24-26], our data also
demonstrated that elevated HbA1C levels significantly
conferred to clinical discriminators not only for the pres-
ence of CAD, but also for the severity of coronary lesions
in patients with CAD. However, both chi-squared for
trend and multivariate Cox proportional regression ana-
lysis with adjustment for all potential confounders in our
study showed the usefulness of HbA1c in predicting the
early outcome of the enrolled population. Kaplan-Meier
curve for cumulative event-free survival based on the ter-
tiles of baseline plasma HbA1c levels apparently showed
that the elevated HbA1c levels (>6.3%) were generally
associated with increased early adverse outcome. More
interestingly, subgroup analysis indicated that the predict-
ive power of plasma HbA1c existed only in patients with
DM who presented as stable CAD but not in populations
without the history of DM. The results clearly suggested
the important role of baseline plasma HbA1c in diabetic
patients with CAD.
It has been demonstrated that DM is a risk for the
development of CAD and individuals who had DM will
suffer from more intensive atherosclerotic lesions and
more cardiovascular events [29,30]. Previous studies have
Figure 3 ROC curves showed discriminatory power of serum hemoglobin A1C levels on coronary artery disease.
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and HbA1C level with the presence of CAD in a variety of
individuals such as in patients with or without diabetes, in
asymptomatic persons, even in general population with
undiagnosed diabetes [3,22,24,31-33]. However, to the best
of our knowledge, there is no data available regarding the
role of HbA1C in the prognostic predictor of patients with
DM. In this study, we prospectively enrolled a large cohortFigure 4 Association of tertiles of serum hemoglobin A1C levels andof patients who presented as typical angina-like chest pain
(stable angina) to evaluating the relationship between
HbA1C and CAD. We found that HbA1C could signifi-
cantly confer to clinical discriminators not only for the
presence of CAD but also for the severity of coronary le-
sions in these patients. The results analyzed by univariate
and multivariate logistic regression models indicated that
plasma HbA1C levels was an independent predictors of12-month outcome.
Table 3 Unadjusted and adjusted predictive value of serum hemoglobin A1C levels for 12-month total outcome
Variables Unadjusted Adjusted
HR (95% CI) P-value HR (95% CI) P-value
Family history of CAD 2.05(1.03-4.06) 0.040 1.99(1.01-3.93) 0.046
Numbers of affected coronary arteries 1.44(1.20-1.73) <0.001 1.42(1.19-1.69) <0.001
Hemoglobin A1C 1.29(1.07-1.57) 0.008 1.28(1.12-1.45) <0.001
CAD = coronary artery disease.
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of CAD and lipid parameters. AUC evaluation suggested a
well discriminatory power of HbA1c for CAD in our
population studied.
Indeed, HbA1C has been proposed as reliable tool for
not only diagnosing DM but also identifying individuals
at high risk of cardiovascular events with and without
DM [1,19]. Although accumulating evidence suggested
that an elevated HbA1C level was clearly linked to a poor
prognostic outcome in patients with AMI or ACS, even
after cardiac surgery or coronary stent implantation, the
prognostic value of baseline HbA1c in patients of stable
angina has not been well established [11,19,20]. In the
present study, we detected that the higher level of plasma
HbA1c was relevant to adverse prognosis in patients with
stable CAD during an average of 12 month follow-up.
Among adverse cardiovascular events, the patients withFigure 5 Kaplan-Meier curve for cumulative event-free survival basedhigher HbA1c were more prone to receive the coronary
intervention of revascularizations in agreement with pre-
vious studies. Therefore, the present study confirmed and
extended previous studies regarding the role of HbA1c in
predicting the severity and early outcome in stable CAD.
The underlying hypothesis of the current results might
consisted in that the high levels of HbA1c were not only
associated with the long-term disorder of glycolipid me-
tabolism but also connected with low-grade systematic
inflammation and atherosclerotic plaques progress [34].
Our data might supported this hypothesis because we
found that higher levels of HbA1c in the population
studied were clearly associated with the adverse baseline
characteristics such as higher cardiovascular risk profile
and higher inflammatory biomarkers such as hs-CRP,
leukocyte counts, fibrinogen, D-dimer, uric acid and so on.
Our data were also in agreement with previous evidenceon tertiles of baseline plasma hemoglobin A1c levels.
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above inflammatory biomarkers, chemical parameters, ei-
ther alone or combined. These markers or risk factors had
a direct role on the progression of atherosclerotic artery
disease and adverse cardiovascular events [7,31,35-39].
Moreover, previous studies also suggested that the higher
plasma HbA1c might indicate a potential impact of
hyperglycemia on the vasculature before the establish-
ments of formal diagnosis for clinically DM and/or
overt atherosclerosis disease [7,40]. Therefore, as a long
half-life protein, HbA1c might be involved in both
chronic inflammatory response and acute active phase
of ACS, resulting in accelerating the progress and rup-
ture of atherosclerotic lesions.
Summarily, in this prospective, a large cohort, short-
term outcome study, the data clearly suggested that high
level of plasma HbA1C (>6.3%) was an independent pre-
dictor for the presence and severity of CAD as well as the
early outcome of patients with stable angina. Long-term
follow-up may be needed for further revealing more infor-
mation regarding the role of HbA1C in diabetic patients
with stable CAD.
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